Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...

Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) is expected to release its earnings data before the market opens on ...

FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additional ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a Market Perform recommendation. As of February 19, 2025, the average one ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Terns Pharmaceuticals reported a strong financial position, with a cash balance of $373 million as of Q3 2024. InvestingPro analysis reveals that the company holds more cash than debt on its balance ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...